Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics.
暂无分享,去创建一个
Jun Zhou | W. Volberg | Bryan J. Koci | W. Su | Jing Lin | Walter A Volberg | Bryan J Koci | Weiguo Su | Jing Lin | Jun Zhou
[1] W. Trautwein,et al. “Run-down” of the Ca current during long whole-cell recordings in guinea pig heart cells: role of phosphorylation and intracellular calcium , 1988, Pflügers Archiv.
[2] B. Sakmann,et al. Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches , 1981, Pflügers Archiv.
[3] Elisabetta Poluzzi,et al. Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs: a call for consensus , 2001, European Journal of Clinical Pharmacology.
[4] J. Westphal. Macrolide - induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. , 2001, British journal of clinical pharmacology.
[5] Jun Chen,et al. A structural basis for drug-induced long QT syndrome. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[6] W. Rafflenbeul,et al. QT prolongation due to roxithromycin , 2000, Postgraduate medical journal.
[7] D M Roden,et al. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[8] W. Crumb,et al. Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias , 2000, Expert opinion on pharmacotherapy.
[9] Y. Kurachi,et al. Inhibitory effects of vesnarinone on cloned cardiac delayed rectifier K(+) channels expressed in a mammalian cell line. , 2000, The Journal of pharmacology and experimental therapeutics.
[10] J. Camm,et al. Risk of torsades de pointes with non-cardiac drugs , 2000, BMJ : British Medical Journal.
[11] G. Amsden,et al. Macrolide Drug Interactions: An Update , 2000, The Annals of pharmacotherapy.
[12] John S. Mitcheson,et al. Trapping of a Methanesulfonanilide by Closure of the Herg Potassium Channel Activation Gate , 2000, The Journal of general physiology.
[13] M. Jiang,et al. Use-dependent 'agonist' effect of azimilide on the HERG channel. , 1999, The Journal of pharmacology and experimental therapeutics.
[14] H. Yoshida,et al. [Tissue penetration properties of macrolide antibiotics--comparative tissue distribution of erythromycin-stearate, clarithromycin, roxithromycin and azithromycin in rats]. , 1999, The Japanese journal of antibiotics.
[15] Cavero,et al. QT interval prolongation by non-cardiovascular drugs: issues and solutions for novel drug development. , 1999, Pharmaceutical science & technology today.
[16] K. Eguchi,et al. Clarithromycin associated with torsades de pointes. , 1999, Japanese circulation journal.
[17] M. Keating,et al. MiRP1 Forms IKr Potassium Channels with HERG and Is Associated with Cardiac Arrhythmia , 1999, Cell.
[18] B. Knollmann,et al. Cardiac actions of erythromycin: influence of female sex. , 1998, JAMA.
[19] A. Cohen,et al. The influence of cisapride and clarithromycin on QT intervals in healthy volunteers , 1998, Clinical pharmacology and therapeutics.
[20] S. Tang,et al. QT prolongation and Torsades de Pointes associated with clarithromycin. , 1998, The American journal of medicine.
[21] C. January,et al. Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. , 1998, Biophysical journal.
[22] A. Brown,et al. A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG , 1997, FEBS letters.
[23] M. Sekkarie,et al. Torsades de pointes in two chronic renal failure patients treated with cisapride and clarithromycin. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[24] K. Hussain,et al. A Review of Erythromycin-Induced Malignant Tachyarrhythmia— Torsade de Pointes , 1997, Angiology.
[25] D. Rampe,et al. Blockade of the human cardiac K+ channel Kv1.5 by the antibiotic erythromycin , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.
[26] C. Lipinski,et al. Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida. , 1997, Journal of medicinal chemistry.
[27] C. January,et al. Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride. , 1997, The American journal of physiology.
[28] P. Saikku,et al. Oral empiric treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin. The Scandinavian Sparfloxacin Study Group. , 1996, Chest.
[29] C Antzelevitch,et al. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes. , 1996, Journal of the American College of Cardiology.
[30] D. Snyders,et al. High affinity open channel block by dofetilide of HERG expressed in a human cell line. , 1996, Molecular pharmacology.
[31] Gary Yellen,et al. The inward rectification mechanism of the HERG cardiac potassium channel , 1996, Nature.
[32] M. Sanguinetti,et al. A mechanistic link between an inherited and an acquird cardiac arrthytmia: HERG encodes the IKr potassium channel , 1995, Cell.
[33] O. G. Nilsen. Pharmacokinetics of macrolides. Comparison of plasma, tissue and free concentrations with special reference to roxithromycin , 1995, Infection.
[34] D. Zipes,et al. Electrophysiological Mechanisms in a Canine Model of Erythromycin‐Associated Long QT Syndrome , 1993, Circulation.
[35] E. Mini,et al. Pharmacokinetic Drug Interactions of Macrolides , 1992, Clinical pharmacokinetics.
[36] E. Mini,et al. Clinical Pharmacokinetic Properties of the Macrolide Antibiotics , 2012 .
[37] H. C. Hartzell,et al. Modulation of the delayed rectifier potassium current in frog cardiomyocytes by beta‐adrenergic agonists and magnesium. , 1989, The Journal of physiology.
[38] E. Mini,et al. Clinical Pharmacokinetic Properties of the Macrolide Antibiotics , 1989, Clinical pharmacokinetics.
[39] E. Mini,et al. Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part I). , 1989, Clinical pharmacokinetics.